U.S. National Institutes of Health

Division of Cancer Treatment and Diagnosis (DCTD)

| |

Featured Trials

DCTD Programs

Last Updated: 08/25/09

Featured Trials

Comparing Surgical Treatment for Small NSCLC Tumors

Marker Validation of Erlotinib in Lung Cancer

Trial Assigning IndividuaLized Options for Treatment (Rx)

National Lung Screening Trial

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Phase III Study of R-CHOP versus R-Dose-Adjusted-Epoch with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Randomized Trials Evaluate the Addition of Bevacizumab or Cetuximab in Combination with Chemotherapy in Patients with Resected Colon Cancer

Incorporating Novel Agents into the Treatment of Pediatric Acute Lymphoblastic Leukemia

Phase III Treatment Trials in Early Stage Non-Small Cell Lung Cancer Will Assess the Clinical Benefit of Bevacizumab as Part of Adjuvant Therapy and Surgical Resection Techniques

Phase III Trial in Advanced Non-Small Cell Lung Cancer Will Assess FDG-PET/CT as Predictive Marker of Response and Patient Outcome

Phase III Trial Evaluating Radiotherapy to the Pelvic Lymph Nodes with Short-Term Androgen Deprivation in Prostate Cancer Patients with a Rising Prostate-Specific Antigen after Radical Prostatectomy

International Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study-The ALTTO Study

Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer

Fludeoxyglucose F 18 PET/CT Scans in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Undergoing Chemotherapy

Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma